Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy.
BACKGROUND
Several cases of low-grade endometrial stromal sarcomas in women with breast cancer have been reported to be associated with tamoxifen therapy. Estrogen receptor expression has been used to characterize the partial estrogenic action of tamoxifen on the endometrium and has been found in tamoxifen-associated endometrial pathologies.


METHODS
A low-grade endometrial stromal sarcoma in a woman with a history of breast cancer treated with adjuvant tamoxifen is presented. Steroid receptor studies performed on the tumor were negative for estrogen and positive for progesterone.


CONCLUSIONS
The absence of estrogen receptor expression suggests that endometrial stromal sarcomas are not necessarily caused by the estrogenic properties of tamoxifen.
Liao
J B
JB
Department of Obstetrics and Gynecology, The George Washington University Medical Center, Washington, DC, USA.
Lin
J Y
JY
D000328:Adult; D016889:Endometrial Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011960:Receptors, Estrogen / Q000032:analysis*; D012509:Sarcoma / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D013629:Tamoxifen / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen